96 related articles for article (PubMed ID: 12045833)
1. Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease.
Castro RR; Porphirio G; Serra SM; Nóbrega AC
Braz J Med Biol Res; 2002 Jun; 35(6):685-9. PubMed ID: 12045833
[TBL] [Abstract][Full Text] [Related]
2. Reduction of QTc interval dispersion. Potential mechanism of cardiac protection of pyridostigmine bromide.
Castro RR; Serra SM; Nóbrega AC
Arq Bras Cardiol; 2000 Sep; 75(3):205-13. PubMed ID: 11018806
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects.
Nóbrega AC; dos Reis AF; Moraes RS; Bastos BG; Ferlin EL; Ribeiro JP
Clin Auton Res; 2001 Feb; 11(1):11-7. PubMed ID: 11503945
[TBL] [Abstract][Full Text] [Related]
4. Cholinergic stimulation with pyridostigmine increases heart rate variability and baroreflex sensitivity in rats.
Soares PP; da Nóbrega AC; Ushizima MR; Irigoyen MC
Auton Neurosci; 2004 Jun; 113(1-2):24-31. PubMed ID: 15296792
[TBL] [Abstract][Full Text] [Related]
5. Cholinergic stimulation with pyridostigmine prevents the impairment in ventricular function during mental stress in coronary artery disease patients.
Nobrega AC; Loures DL; Pontes PV; Sant'anna ID; Mesquita ET
Int J Cardiol; 2008 Apr; 125(3):418-21. PubMed ID: 17397949
[TBL] [Abstract][Full Text] [Related]
6. Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress.
Nóbrega AC; Carvalho AC; Santos KB; Soares PP
Clin Auton Res; 1999 Feb; 9(1):11-6. PubMed ID: 10212743
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic stimulation with pyridostigmine protects myocardial infarcted rats against ischemic-induced arrhythmias and preserves connexin43 protein.
Santos-Almeida FM; Girão H; da Silva CA; Salgado HC; Fazan R
Am J Physiol Heart Circ Physiol; 2015 Jan; 308(2):H101-7. PubMed ID: 25416192
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure.
Behling A; Moraes RS; Rohde LE; Ferlin EL; Nóbrega AC; Ribeiro JP
Am Heart J; 2003 Sep; 146(3):494-500. PubMed ID: 12947369
[TBL] [Abstract][Full Text] [Related]
9. Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine.
Serra SM; Costa RV; Bastos BG; Bousquet Santos K; Ramalho SH; da Nóbrega AC
Arq Bras Cardiol; 2001 Apr; 76(4):279-84. PubMed ID: 11323731
[TBL] [Abstract][Full Text] [Related]
10. Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease.
Castro RR; Serra SM; Porphirio G; Mendes FS; Oliveira LP; Nóbrega AC
Int J Cardiol; 2006 Feb; 107(1):138-9. PubMed ID: 16337518
[TBL] [Abstract][Full Text] [Related]
11. Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects.
Sant'anna ID; de Sousa EB; de Moraes AV; Loures DL; Mesquita ET; da Nóbrega AC
Clin Sci (Lond); 2003 Aug; 105(2):161-5. PubMed ID: 12627998
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia.
Castro RR; Porphirio G; Serra SM; Nóbrega AC
Heart; 2004 Oct; 90(10):1119-23. PubMed ID: 15367503
[TBL] [Abstract][Full Text] [Related]
13. Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans.
Nóbrega AC; Carvalho AC; Bastos BG
Braz J Med Biol Res; 1996 Nov; 29(11):1461-5. PubMed ID: 9196546
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibition reduces arrhythmias in asymptomatic Chagas disease.
Castro RRT; Porphirio G; Xavier SS; Moraes RS; Ferlin EL; Ribeiro JP; da Nóbrega ACL
Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28715142
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic stimulation with pyridostigmine, hemodynamic and echocardiographic analysis in healthy subjects.
de Pontes PV; Bastos BG; Romeo Filho LJ; Mesquita ET; da Nóbrega AC
Arq Bras Cardiol; 1999 Mar; 72(3):297-306. PubMed ID: 10513041
[TBL] [Abstract][Full Text] [Related]
16. Subacute pyridostigmine exposure increases heart rate recovery and cardiac parasympathetic tone in rats.
Bharadwaj M; Pope C; Davis M; Katz S; Cook C; Maxwell L
Clin Exp Pharmacol Physiol; 2017 Aug; 44(8):872-879. PubMed ID: 28440910
[TBL] [Abstract][Full Text] [Related]
17. Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure.
Serra SM; Costa RV; Teixeira De Castro RR; Xavier SS; Nóbrega AC
J Card Fail; 2009 Mar; 15(2):124-9. PubMed ID: 19254671
[TBL] [Abstract][Full Text] [Related]
18. Acute electrophysiologic consequences of pyridostigmine inhibition of cholinesterase in humans.
Zimerman LI; Liberman A; Castro RR; Ribeiro JP; Nóbrega AC
Braz J Med Biol Res; 2010 Feb; 43(2):211-6. PubMed ID: 20084332
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the dose-dependent effects of atropine by low-dose pyridostigmine: quantification by spectral analysis of heart rate fluctuations in healthy human beings.
Izraeli S; Alcalay M; Benjamini Y; Wallach-Kapon R; Tochner Z; Akselrod S
Pharmacol Biochem Behav; 1991 Jul; 39(3):613-7. PubMed ID: 1784590
[TBL] [Abstract][Full Text] [Related]
20. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial.
Schreglmann SR; Büchele F; Sommerauer M; Epprecht L; Kägi G; Hägele-Link S; Götze O; Zimmerli L; Waldvogel D; Baumann CR
Eur J Neurol; 2017 Apr; 24(4):545-551. PubMed ID: 28224720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
